Overview
Mirikizumab is one of the newest IBD biologics, selectively targeting IL-23 p19 (like risankizumab). It is approved for moderate-to-severe ulcerative colitis. Induction is given as IV infusions, followed by subcutaneous maintenance injections.
Key Uses
Moderate-to-severe ulcerative colitis
Patients who have failed conventional therapy or prior biologics
How It Works
Humanised IgG4 monoclonal antibody targeting IL-23 p19 subunit
Induction: 300 mg IV at weeks 0, 4, and 8; maintenance: 200 mg SC every 4 weeks
Selective IL-23 blockade preserves IL-12 pathways important for immune protection
Safety & Self-Care
TB and hepatitis B screening before starting
Generally well tolerated; injection site reactions and upper respiratory infections most common
Attend all induction infusions and maintenance injection appointments
Avoid live vaccines during treatment
Regular clinical review to assess response
Contact Your IMCC Team
Contact your IMCC team if symptoms worsen, you develop signs of infection, or before any planned surgery or pregnancy.
Share this with someone who needs it: